Skip to main content

Advertisement

SpringerLink
Log in

The future of ipriflavone in the management of osteoporotic syndromes

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Norris RJ (1992) Medical costs of osteoporosis. Bone 13:S11-S16

    Article  PubMed  Google Scholar 

  2. Heggeness MH (1993) Spine fracture with neurological deficit in osteoporosis. Osteoporosis Int 3:215–221

    Article  CAS  Google Scholar 

  3. White BL, Fisher WD, Laurin CA (1987) Rate of mortality for elderly patients after fracture of the hip in the 1980’s. J Bone Joint Surg 69A:1335–1340

    Google Scholar 

  4. Conference Report (1991) Am J Med 90:107–110

    Google Scholar 

  5. Miller PD, Bonnick SL, Rosen CJ (1996) Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 58:207–214

    PubMed  CAS  Google Scholar 

  6. Report of WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva: 5–6

  7. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas P (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700

    Article  PubMed  CAS  Google Scholar 

  8. Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gardsell P, Obrant KJ (1995) Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 10:1823–1829

    PubMed  CAS  Google Scholar 

  9. Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG (1996) The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 58: 216–220

    PubMed  CAS  Google Scholar 

  10. Eiken P, Kolthoff N (1995) Long-term oral hormonal replacement therapy. Maturitas 22:97–103

    Article  PubMed  CAS  Google Scholar 

  11. Overgaard K (1994) Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 55: 82–86

    Article  PubMed  CAS  Google Scholar 

  12. Reginster JY, Denis D, Deroisy R, Lecart MP, De Longue-ville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P (1994) Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69–73

    Article  PubMed  CAS  Google Scholar 

  13. Overgaard K, Hansen MA, Herss Nielsen VA, Riis BJ, Chris-tiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment. Am J Med 89:1–6

    Article  PubMed  CAS  Google Scholar 

  14. Overgaard K (1994) Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int 55:79–81

    Article  PubMed  CAS  Google Scholar 

  15. Sambrook PN (1995) The treatment of postmenopausal osteoporosis (editorial). N Engl J Med 333:1495–1496

    Article  PubMed  CAS  Google Scholar 

  16. Maconi G, Bianchi Porro G (1995) Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889–1890

    PubMed  CAS  Google Scholar 

  17. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557–567

    Article  PubMed  CAS  Google Scholar 

  18. Wimalawansa SJ (1995) Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 99:36–42

    Article  PubMed  CAS  Google Scholar 

  19. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Int Med 123: 401–408

    PubMed  CAS  Google Scholar 

  20. Albanese CV, Cudd A, Argentino L, Zambonin-Zallone A, Macintyre I (1994) Ipriflavone directly inhibits osteoclastic activity. Biochem Biophys Res Comm 930–936

  21. Kakai Y, Kawase K, Nakano T, Mikuni-Takagaki Y, Saito S (1992) Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 51 (suppl 1):S11-S15

    Article  PubMed  CAS  Google Scholar 

  22. Mazzuoli GF, Romagnoli E, Carnevale L, Scarda A, Scarnecchia M, Pacitti MT, Rosso R, Minisola V (1992) Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. Bone Miner 19:S27-S33

    Article  PubMed  Google Scholar 

  23. Agnusdei D, Camporeale A, Gonnelli S, Gennari C, Baroni MC, Passeri M (1992) Short-term treatment of Paget’s disease of bone with ipriflavone. Bone Miner 19:S35-S42

    Article  PubMed  Google Scholar 

  24. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333–337

    PubMed  CAS  Google Scholar 

  25. Gambacciani M, Spinetti A, Piaggesi L, Cappagli B, Taponeco F, Manetti P, Weiss C, Teti GC, La Commare P, Facchini V (1994) Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormonereleasing hormone agonists. Bone Miner 26:19–26

    Article  PubMed  CAS  Google Scholar 

  26. Agnusdei D, Gennari C, Bufalino L (1995) Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int 5:462–466

    Article  CAS  Google Scholar 

  27. Melis GB, Paoletti AM, Cagnacci A (1996) Ipriflavone prevents bone loss in postmenopausal women. Menopause 3:27–32

    Google Scholar 

  28. Valente M, Bufalino L, Castiglione GN, D’Angelo R, Mancuso A, Galoppi P, Zichella L (1994) Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377–380

    Article  PubMed  CAS  Google Scholar 

  29. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82–91

    Google Scholar 

  30. Passeri M, Biondi M, Costi D, Dall’Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. J Miner Electrolyte Metab 9:137–144

    CAS  Google Scholar 

  31. Adami S, Bufalino L, Cervetti R, DiMarco C, DiMunno O, Fantasia L, Isaia C, Serni U, Vecchiet L, Passeri M (1997) Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int 7:119–125

    Article  CAS  Google Scholar 

  32. Civitelli R, Abbasi-Jarhomi H, Halstead LR, Dimaragonas A (1995) Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int 56:215–219

    Article  PubMed  CAS  Google Scholar 

  33. Melis GB, Paoletti AM, Bartolini R, Tosti Balducci M, Massi GB, Bruni V, Becorpi A, Ottanelli S, Fioretti P, Gambacciani M, Spinetti A, D’Antona N, De Leo V, Agnusdei D, Camporeale A, Gennari C (1992) Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 19:S49-S56

    Article  PubMed  CAS  Google Scholar 

  34. Overgaard K, Hansen MA, Brik Jensen S, Christiansen C (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556–561

    Article  PubMed  CAS  Google Scholar 

  35. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seelman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Bone and Mineral Diseases, The Jewish Hospital of St. Louis, Washington University of Medicine, 216 South Kingshighway, St. Louis, MO, USA

    L. V. Avioli

Authors
  1. L. V. Avioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avioli, L.V. The future of ipriflavone in the management of osteoporotic syndromes. Calcif Tissue Int 61 (Suppl 1), S33–S35 (1997). https://doi.org/10.1007/s002239900383

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002239900383

Keywords

Search

Navigation